Replies to post #220257 on Biotech Values

[jbog]

The total amount spent on HCV is a fraction of what it was a mere 3 years ago. It will have to determined if the patient pool is drying up or whether Abbve's pricing model decimated this market.

[DewDiligence]

What ABBV said about Mavyret on 2Q18 CC:

https://twitter.com/DewDiligence/status/1022884519802806275